These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23289680)

  • 1. One-component nanomedicine.
    Su H; Koo JM; Cui H
    J Control Release; 2015 Dec; 219():383-395. PubMed ID: 26423237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine concepts in the general medical curriculum: initiating a discussion.
    Sweeney AE
    Int J Nanomedicine; 2015; 10():7319-31. PubMed ID: 26677322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prudent precaution in clinical trials of nanomedicines.
    Marchant GE; Lindor RA
    J Law Med Ethics; 2012; 40(4):831-40. PubMed ID: 23289685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A portrait of nanomedicine and its bioethical implications.
    Hall RM; Sun T; Ferrari M
    J Law Med Ethics; 2012; 40(4):763-79. PubMed ID: 23289679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsible conduct in nanomedicine research: environmental concerns beyond the common rule.
    Resnik DB
    J Law Med Ethics; 2012; 40(4):848-55. PubMed ID: 23289687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond human subjects: risk, ethics, and clinical development of nanomedicines.
    Kimmelman J
    J Law Med Ethics; 2012; 40(4):841-7. PubMed ID: 23289686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The need for rules and regulations.
    Helmus MN
    Nat Nanotechnol; 2007 Jun; 2(6):333-4. PubMed ID: 18654297
    [No Abstract]   [Full Text] [Related]  

  • 8. What is unique about nanomedicine? The significance of the mesoscale.
    Khushf G; Siegel RA
    J Law Med Ethics; 2012; 40(4):780-94. PubMed ID: 23289680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation nanomedicines and nanosimilars: EU regulators' initiatives relating to the development and evaluation of nanomedicines.
    Ehmann F; Sakai-Kato K; Duncan R; Hernán Pérez de la Ossa D; Pita R; Vidal JM; Kohli A; Tothfalusi L; Sanh A; Tinton S; Robert JL; Silva Lima B; Amati MP
    Nanomedicine (Lond); 2013 May; 8(5):849-56. PubMed ID: 23656268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated Regulatory Considerations for Nanomedicines.
    Subin TS; Vijayan V; Kumar KJR
    Pharm Nanotechnol; 2017; 5(3):180-191. PubMed ID: 28641516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory aspects on nanomedicines.
    Sainz V; Conniot J; Matos AI; Peres C; Zupancic E; Moura L; Silva LC; Florindo HF; Gaspar RS
    Biochem Biophys Res Commun; 2015 Dec; 468(3):504-10. PubMed ID: 26260323
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.